New drug combo shows promise for tough cancers
NCT ID NCT07644039
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PM54 (a new drug) combined with pembrolizumab (an immunotherapy)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced cancers that have not responded to prior therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the drug combination may not prove effective or may cause unexpected side effects. Success in this trial does not guarantee future approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Dallas
RECRUITINGIrving, Texas, 75039, United States
-
NEXT Houston
RECRUITINGHouston, Texas, 77054, United States
-
NEXT Virginia
NOT_YET_RECRUITINGFairfax, Virginia, 22031, United States
-
START Dallas
RECRUITINGFort Worth, Texas, 76104, United States
-
START New York
NOT_YET_RECRUITINGNew York, New York, 11042, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States